Corporate Information – Page 20 – Alligator Bioscience

2020-04-07

Regulatory

Alligator Bioscience increases focus on clinical development

Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...

2020-04-01

Regulatory

Lund, Sweden, 1 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new pati ...

2020-03-31

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2020-03-05

Lund, Sweden, 5 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed inte ...

2019-12-17

Lund, Sweden, December 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successful ...

2019-12-11

Lund, Sweden, December 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that CFO (Chief Financial Officer) Per-Olo ...

2019-11-29

Lund, November 29, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX today announced that the company has appointed Dr Malin Carlsson as ...

2019-11-13

Lund, Sweden, November 13, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...

2019-11-08

Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti ...